Abstract
Introduction: Bulevirtide (BLV) has been recently approved for the treatment of HDV-related chronic hepatitis or compensated cirrhosis in Europe, but its effectiveness and safety in patients with advanced cirrhosis and severe portal hypertension are still unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
